Fig. 3.

Ulcer recurrence rates after IL-1β administration according to groups. Since preliminary study showed that 100% healing of gastric ulcer was noted after 24–28 weeks, converting into S stage of gastric ulcer, and ulcer was recurred after 24–48 hr of intraperitoneal injections of 200 µg/kg of IL-1β, we administered IL-1β to all rats of experimental groups and sacrificed 48 hr later. 11 out of 12 rats with scarred gastric ulcer (91.7%) in Group I were recurred after IL-1β injection and 9 out of 12 rats (75.0%) showed ulcer recurrence in Group II. However, only 2 out of 12 (16.7%) showed ulcer recurrence and the remaining 10 out of 12 rats remained intact even after the administration of IL-1β, signifying that considerable resistance of ulcer recurrence was achieved in group treated with gastroprotectant.